Nigeria vs Papua New Guinea: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage
Nigeria
28.0%
in 2024
Papua New Guinea
41.0%
in 2024
Nigeria rank
145th
Papua New Guinea rank
142nd
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage over time
- Nigeria
- Papua New Guinea
How they compare
Papua New Guinea currently reports 41.0% against 28.0% in Nigeria, a difference of 13.0%.
That makes Papua New Guinea's figure about 1.5 times Nigeria's.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Nigeria ahead.
Nigeria ranks 145th and Papua New Guinea ranks 142nd of 146 countries.
Nigeria has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Nigeria | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 52.2% | 29.2% | 23.0% | Nigeria |
| 2020s | 46.6% | 36.6% | 10.0% | Nigeria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage, Nigeria or Papua New Guinea?
- Papua New Guinea, at 41.0% against 28.0% in Nigeria as of 2024.
- What is the difference in pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage between Nigeria and Papua New Guinea?
- 13.0%, with Papua New Guinea ahead.
- How many years of comparable data are there for Nigeria and Papua New Guinea?
- 10 years are reported by both, from 2015 to 2024.
- How do Nigeria and Papua New Guinea rank globally for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- Nigeria ranks 145th and Papua New Guinea ranks 142nd of 146 countries.
- Where does this data come from?
- WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.